Clinical Treatment Value of Acute Myeloid Leukemia in Different Genotypes
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v5i2.2001
Abstract
Acute myeloid leukemia (AML), a disease formed by mutations in pluripotent stem cells or mildly differentiated precursor cells, is a clonal malignant disease of the hematopoietic system. In recent years, with the application of immunology, cytogenetics, and molecular biology, a deeper understanding of the biological properties of AML tumor cells has laid the foundation for accurate classification, diagnosis, prognosis, and selection of the optimal treatment for AML. This article reviewed the relevant literature on the difference in clinical diagnosis and treatment value of AML in different genotypes in recent years.
Keywords
acute myeloid leukemia, diagnosis, treatment
Full Text
PDF - Viewed/Downloaded: 2 TimesReferences
[1] Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges[J]. Blood Reviews, 2019, 36: 70-87.
[2] Lin K, Jia H, Cao M, et al. Epidemiological characteristics of leukemia in China, 2005-2017: a log-linear regression and age-period-cohort analysis[J]. BMC Public Health, 2023, 23(1): 1647.
[3] Khwaja A, Bjorkholm M, Gale RE, et al. Acute myeloid leukemia [J]. Nature Reviews Disease Primers, 2016, 2(1): 16010.
[4] Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes[J]. Blood, 2009, 114(5): 937-951.
[5] Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms[J]. Leukemia, 2022, 36(7): 1703-1719.
[6] Solh M, Yohe S, Weisdorf D, et al. Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy[J]. American Journal of Hematology, 2014, 89(12): 1121-1131.
[7] Anžej Doma S, Škerget M, Pajič T, et al. Improved survival of AML patients by addition of cladribine to standard induction chemotherapy[J]. Annals of Hematology, 2020, 99(3): 519-525.
[8] Schlenk RF, Jaramillo S, Müller-Tidow C. What's new in consolidation therapy in AML?[J]. Seminars in Hematology, 2019, 56(2): 96-101.
[9] Jimenez-Chillon C, Dillon R, Russell N. Optimal post-remission consolidation therapy in patients with AML[J]. Acta Haematologica, 2023.
[10] Shahzad M, Tariq E, Chaudhary SG, et al. Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis[J]. Leukemia & Lymphoma, 2022, 63(14): 3409-3417.
[11] Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission[J]. Blood, 2016, 127(1): 62-70.
[12] Ge S, Wang J, He Q, et al. Auto-hematopoietic stem cell transplantation or chemotherapy? Meta-analysis of clinical choice for AML[J]. Annals of Hematology, 2024.
[13] Wang Y, Wu N, Liu D, et al. Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment[J]. Current Genomics, 2017, 18(5): 378-384.
[14] Iijima-Yamashita Y, Matsuo H, Yamada M, et al. Multiplex fusion gene testing in pediatric acute myeloid leukemia[J]. Pediatrics International: Official Journal of the Japan Pediatric Society, 2018, 60(1): 47-51.
[15] Marschalek R. MLL leukemia and future treatment strategies[J]. Archiv Der Pharmazie, 2015, 348(4): 221-228.
[16] Takagi K, Tasaki T, Yamauchi T, et al. Successful Administration of Recombinant Human Soluble Thrombomodulin α (Recomodulin) for Disseminated Intravascular Coagulation during Induction Chemotherapy in an Elderly Patient with Acute Monoblastic Leukemia Involving the t(9;11)(p22;q23) MLL/AF9 Translocation[J]. Case Reports in Hematology, 2011, 2011: 273070.
[17] Beez S, Demmer P, Puccetti E. Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides[J]. PloS One, 2012, 7(11): e48636.
[18] [The First Switched Time of PML/RARα Fusion Gene in Patients with Acute Promyelocytic Leukemia and Its Clinical Significance] - PubMed[EB/OL]. [2024-01-31]. https://pubmed.ncbi.nlm.nih.gov/26708869/.
[19] De Braekeleer E, Douet-Guilbert N, De Braekeleer M. RARA fusion genes in acute promyelocytic leukemia: a review[J]. Expert Review of Hematology, 2014, 7(3): 347-357.
[20] Hatlen MA, Wang L, Nimer SD. AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches[J]. Frontiers of Medicine, 2012, 6(3): 248-262.
[21] Fu L, Huang W, Jing Y, et al. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia[J]. The FEBS journal, 2014, 281(4): 1123-1131.
[2] Lin K, Jia H, Cao M, et al. Epidemiological characteristics of leukemia in China, 2005-2017: a log-linear regression and age-period-cohort analysis[J]. BMC Public Health, 2023, 23(1): 1647.
[3] Khwaja A, Bjorkholm M, Gale RE, et al. Acute myeloid leukemia [J]. Nature Reviews Disease Primers, 2016, 2(1): 16010.
[4] Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes[J]. Blood, 2009, 114(5): 937-951.
[5] Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms[J]. Leukemia, 2022, 36(7): 1703-1719.
[6] Solh M, Yohe S, Weisdorf D, et al. Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy[J]. American Journal of Hematology, 2014, 89(12): 1121-1131.
[7] Anžej Doma S, Škerget M, Pajič T, et al. Improved survival of AML patients by addition of cladribine to standard induction chemotherapy[J]. Annals of Hematology, 2020, 99(3): 519-525.
[8] Schlenk RF, Jaramillo S, Müller-Tidow C. What's new in consolidation therapy in AML?[J]. Seminars in Hematology, 2019, 56(2): 96-101.
[9] Jimenez-Chillon C, Dillon R, Russell N. Optimal post-remission consolidation therapy in patients with AML[J]. Acta Haematologica, 2023.
[10] Shahzad M, Tariq E, Chaudhary SG, et al. Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis[J]. Leukemia & Lymphoma, 2022, 63(14): 3409-3417.
[11] Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission[J]. Blood, 2016, 127(1): 62-70.
[12] Ge S, Wang J, He Q, et al. Auto-hematopoietic stem cell transplantation or chemotherapy? Meta-analysis of clinical choice for AML[J]. Annals of Hematology, 2024.
[13] Wang Y, Wu N, Liu D, et al. Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment[J]. Current Genomics, 2017, 18(5): 378-384.
[14] Iijima-Yamashita Y, Matsuo H, Yamada M, et al. Multiplex fusion gene testing in pediatric acute myeloid leukemia[J]. Pediatrics International: Official Journal of the Japan Pediatric Society, 2018, 60(1): 47-51.
[15] Marschalek R. MLL leukemia and future treatment strategies[J]. Archiv Der Pharmazie, 2015, 348(4): 221-228.
[16] Takagi K, Tasaki T, Yamauchi T, et al. Successful Administration of Recombinant Human Soluble Thrombomodulin α (Recomodulin) for Disseminated Intravascular Coagulation during Induction Chemotherapy in an Elderly Patient with Acute Monoblastic Leukemia Involving the t(9;11)(p22;q23) MLL/AF9 Translocation[J]. Case Reports in Hematology, 2011, 2011: 273070.
[17] Beez S, Demmer P, Puccetti E. Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides[J]. PloS One, 2012, 7(11): e48636.
[18] [The First Switched Time of PML/RARα Fusion Gene in Patients with Acute Promyelocytic Leukemia and Its Clinical Significance] - PubMed[EB/OL]. [2024-01-31]. https://pubmed.ncbi.nlm.nih.gov/26708869/.
[19] De Braekeleer E, Douet-Guilbert N, De Braekeleer M. RARA fusion genes in acute promyelocytic leukemia: a review[J]. Expert Review of Hematology, 2014, 7(3): 347-357.
[20] Hatlen MA, Wang L, Nimer SD. AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches[J]. Frontiers of Medicine, 2012, 6(3): 248-262.
[21] Fu L, Huang W, Jing Y, et al. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia[J]. The FEBS journal, 2014, 281(4): 1123-1131.
Copyright © 2024 Xinyao Ji, Changchun Niu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License